Non-interventional study observing the use of Removab for the treatment of patients with malignant ascites due to EpCAM-positive carcinomas.
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Catumaxomab (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
- Acronyms CARMA
- Sponsors Neovii Biotech
- 28 Apr 2014 Status changed from recruiting to completed as reported by German Clinical Trials Register record.
- 06 Sep 2011 New trial record